Live Breaking News & Updates on Peptide Drug Candidate

Stay updated with breaking news from Peptide drug candidate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , European Union , Peptide Drug Candidate , Marketing Authorization , Nasdaq Stockholm ,

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e ....

United Kingdom , Saudi Arabia , United States , United Arab Emirates , Health Care Providers , World Orphan Drug Alliance , European Union , Vector Pharma , Middle East , North Africa , Partner Patrick , Sofia Heigis , Peptide Drug Candidate , Greater China , South Korea , Marketing Authorization , Nasdaq Stockholm ,

Oncopeptides announces successful price negotiations for Pepaxti in Germany

Oncopeptides announces successful price negotiations for Pepaxti in GermanyStockholm – September 26, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Ass. ....

United Kingdom , David Augustsson , European Union , Corporate Affairs , Statutory Health Insurance Funds , Sofia Heigis , Peptide Drug Candidate , Marketing Authorization , Small Cap , Nasdaq Stockholm ,

Oncopeptides AB - Holger Lembrer will leave his role as Chief Financial Officer at Oncopeptides

Oncopeptides AB , a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrer, Chief Financial Officer has decided to leave Oncopeptides to pursue a new role in. | June 15, 2023 ....

United Kingdom , Holger Lembrer , Rolf Gulliksen , Monica Shaw , European Union , Nasdaq Stockholm , Chief Financial Officer , Peptide Drug Candidate , Marketing Authorization , Small Cap , News Publishing , Oncopeptides Ab Publ Stock Exchange , Press Release , Ole Onco Se0009414576 ,

Annual General Meeting in Oncopeptides AB

The shareholders in Oncopeptides AB , reg. no. 556596-6438, with registered office in the municipality of Stockholm, are hereby given notice to attend the Annual General Meeting to be held at. | April 24, 2023 ....

United Kingdom , Vastra Tradgardsgatan , Rolf Gulliksen , European Union , Annual General Meeting , Annual General , Peptide Drug Candidate , Marketing Authorization , Small Cap , Nasdaq Stockholm , News Publishing , Oncopeptides Ab Publ Stock Exchange , Press Release , Eld Onco Se0009414576 ,